Kodiak Sciences Inc. (KOD): Total Assets
$351.53M
As of 2025-12-31
$256.81M
As of 2026-06-30
-19.2%
3-year compound annual growth
-19.9%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $351.53M | +4.8% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $335.58M | -30.0% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $479.37M | -28.1% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $666.63M | -26.3% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $904.22M | -15.3% | 2023-03-28, Balance as of period end |
| 2020-12-31 | $1.07B | +197.4% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $358.87M | +289.3% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $92.19M | n/m | 2020-03-16, Balance as of period end |
| 2017-12-31 | $3.24M | n/a | 2019-03-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $351.53M | +4.8% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $359.07M | +2.7% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $343.32M | +114.1% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $342.73M | +15.2% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $364.98M | +292.7% |
| Prokidney Corp. (PROK) | 2025-12-31 | $335.57M | -23.9% |
| Replimune Group, Inc. (REPL) | 2026-03-31 | $332.39M | -39.7% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $318.94M | -27.6% |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $397.13M | +65.1% |
Compare KOD, CCCC, TSHA, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗